You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

 

1025 Results
Regimen
Cancer Type:
Lung, 
Small Cell
Intent: Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
New Drug Funding Program
    Atezolizumab - In Combination with Etoposide and Platinum for Extensive-Stage Small Cell Lung Cancer
Nov 2023
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
Exceptional Access Program
    darolutamide - For the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel
Mar 2024
Regimen
Cancer Type:
Genitourinary, 
Prostate
Intent: Palliative
Funding:
Exceptional Access Program
    darolutamide - For the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel
Mar 2024
Regimen
Cancer Type:
Endocrine, 
Thyroid
Intent: Palliative
Apr 2023
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Intent: Adjuvant, Curative
May 2023
Regimen
Cancer Type:
Hematologic, 
Leukemia - Acute Myeloid (AML)
Intent: Palliative
May 2023
Regimen
Cancer Type:
Gynecologic, 
Cervix
Intent: Palliative
Funding:
New Drug Funding Program
    Pembrolizumab - Metastatic, Persistent, or Recurrent Carcinoma of the Cervix
New Drug Funding Program
    Bevacizumab (Biosimilar) - Metastatic (Stage IVB), Persistent, or Recurrent Carcinoma of the Cervix
Nov 2023
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Intent: Palliative
Aug 2023
Regimen
Cancer Type:
Hematologic, 
Leukemia - Hairy Cell
Intent: Palliative
Aug 2023
Regimen
Cancer Type:
Hematologic, 
Multiple Myeloma
Intent: Palliative
Funding:
New Drug Funding Program
    Bortezomib - Previously Untreated - Multiple Myeloma Pre-Stem Cell Transplant
ODB - General Benefit
    dexamethasone
Aug 2023

Pages